Docket #: S23-107
Targeting cerebrovascular mucins to improve brain health in age-related diseases
The blood-brain barrier (BBB) lumen is coated by a carbohydrate-rich meshwork known as the brain endothelial glycocalyx layer. Stanford researchers have shown that the brain endothelial glycocalyx is highly dysregulated during aging and neurodegenerative disease. They furthermore identified that a class of glycans known as mucins are highly downregulated on the brain endothelium during aging and in neurodegenerative diseases, which in turn leads to increased BBB leakiness and brain bleeds. Finally, they show brain-endothelial specific viruses (AAVs) can be therapeutically used to overexpress the mucin biosynthetic genes and restore BBB function (less leakiness) and decrease neuroinflammation.
Stage of Development
In vivo: mouse models
Applications
- Neurodegenerative diseases: Alzheimer's, Parkinson's, multiple sclerosis, ALS, traumatic brain injury (TBI), stroke, etc.
Advantages
- Novel way of treating blood brain barrier dysfunction and inflammation
Related Links
Similar Technologies
-
Chemically modified AAVs S21-280Chemically modified AAVs
-
Novel Compounds Inhibit Glucose Metabolism to Boost Neural Stem Cell Function in the Aging Brain S23-475Novel Compounds Inhibit Glucose Metabolism to Boost Neural Stem Cell Function in the Aging Brain
-
First in class covalent inhibitor of Fis1 prevents mitochondrial fragmentation and dysfunction S23-492First in class covalent inhibitor of Fis1 prevents mitochondrial fragmentation and dysfunction